Garcia-Albeniz, Xabier <br/><br/>
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.  [electronic resource] 

 -  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine  Apr 2011 
 - 417-24 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1423-0380 
<br/><br/><label>Standard No.: </label>10.1007/s13277-010-0136-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Camptothecin--analogs & derivatives<br/>Cetuximab<br/>Colorectal Neoplasms--blood<br/>Drug Resistance, Neoplasm<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Irinotecan<br/>Male<br/>Matrix Metalloproteinase 7--blood<br/>Middle Aged<br/>Mutation--genetics<br/>Predictive Value of Tests<br/>Prognosis<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Retrospective Studies<br/>Survival Rate<br/>Treatment Outcome<br/>ras Proteins--genetics